Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $59.20 Consensus Price Target from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given a consensus recommendation of “Buy” by the eight ratings firms that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $59.20.

A number of equities research analysts have recently commented on ARCT shares. Canaccord Genuity Group reduced their price objective on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. HC Wainwright reduced their price objective on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Wells Fargo & Company decreased their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th.

Institutional Trading of Arcturus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Balyasny Asset Management L.P. bought a new position in Arcturus Therapeutics during the fourth quarter valued at about $9,312,000. Schonfeld Strategic Advisors LLC lifted its holdings in Arcturus Therapeutics by 129.7% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company’s stock worth $14,409,000 after purchasing an additional 479,482 shares in the last quarter. J. Goldman & Co LP bought a new position in Arcturus Therapeutics in the 4th quarter worth about $5,024,000. MPM Bioimpact LLC grew its holdings in Arcturus Therapeutics by 109.5% during the 4th quarter. MPM Bioimpact LLC now owns 459,943 shares of the biotechnology company’s stock valued at $7,805,000 after buying an additional 240,435 shares in the last quarter. Finally, Empire Life Investments Inc. increased its position in shares of Arcturus Therapeutics by 85.5% during the fourth quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock valued at $4,742,000 after buying an additional 128,771 shares during the period. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Trading Down 3.9 %

NASDAQ ARCT opened at $9.11 on Friday. Arcturus Therapeutics has a 12 month low of $8.70 and a 12 month high of $45.00. The company has a market cap of $247.06 million, a PE ratio of -4.10 and a beta of 3.41. The stock has a 50 day moving average of $14.89 and a 200-day moving average of $17.42.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The business had revenue of $22.77 million for the quarter, compared to analyst estimates of $44.64 million. As a group, sell-side analysts predict that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.